TPIV News Alert Tapimmune Inc (TPIV) 0.2510 12/26/2014 00:38

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Tapimmune Inc (TPIV) 0.2510 $TPIV

TapImmune CEO Discusses Company's Clinical Programs in Recent Print and Radio Interviews
PR Newswire - Mon Nov 24, 8:06AM CST
TapImmune, Inc. (OTCQB: TPIV), is pleased to point its shareholders to the following press articles published recently in which TapImmune CEO Dr Glynn Wilson has been interviewed. In light of the company's recent news about the establishment of a Phase 2 collaboration and advancement of both clinical programs, the company would like to direct its shareholders to these articles and interviews where Dr Wilson has discussed the progression of clinical trials and TapImmune's technology approach.

Published Review and Analyst Report Boost TapImmune Shares
Marketwired - Wed Nov 19, 3:21PM CST
TapImmune, Inc. (OTCQB: TPIV) was mentioned positively by analysts reacting to recently published comments by Chairman & CEO Glynn Wilson, Ph.D.

VGTI Florida to Collaborate with TapImmune to Advance Targeted Breast and Ovarian Cancer Vaccines into Phase II Clinical Trials
Business Wire - Tue Nov 18, 10:40AM CST
The Vaccine & Gene Therapy Institute of Florida (VGTI Florida), a leading, non-profit biomedical research institute, today announced a new collaborative research agreement with TapImmune, Inc. (OTCQB: TPIV), forming a partnership to advance TapImmune's proprietary, targeted cancer vaccines into mid-stage, Phase II human clinical trials for the treatment of breast and ovarian cancers.

TapImmune Announces Phase II Clinical Trials Collaboration With VGTI Florida to Advance Breast and Ovarian Cancer Vaccines
PR Newswire - Tue Nov 18, 9:00AM CST
TapImmune, Inc. (OTCQB: TPIV), is pleased to announce a new collaborative research agreement with The Vaccine & Gene Therapy Institute of Florida (VGTI Florida), a leading, non-profit biomedical research institute, forming a partnership to advance TapImmune's proprietary, cancer vaccines into Phase II human clinical trials for the treatment of breast and ovarian cancers.

Could This Emerging Drug Developer Really Be Worth A Billion Dollars In Five Years?
ACCESSWIRE - Mon Nov 17, 7:02AM CST
Los Angeles, CA / ACCESSWIRE / November 17, 2014 / Chief Executive Officers of publicly traded companies are often warned not speculate about the future valuation of their firms and that's precisely part of the reason investors are looking more closely at the recent "on the record" statements made by TapImmune's (OTCBB:TPIV) Dr. Glynn Wilson to the Life Sciences Intellectual Property Review.
KITE: 51.96 (+0.45)

The Life Sciences Report Interviews SeeThruEquity Regarding Microcap Life Sciences Companies
ACCESSWIRE - Wed Nov 05, 8:24AM CST
New York, NY / ACCESSWIRE / November 5, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it was recently interviewed by The Life Sciences Report regarding the microcap market for life sciences companies, during which SeeThruEquity analysts discussed DelMar Pharmaceuticals Inc. (OTCQB: DMPI), Manhattan Scientifics Inc. (OTCQB: MHTX) and TapImmune Inc. (OTCQB: TPIV).

The most undervalued, yet comprehensive cancer immunotherapy in development?
ACCESSWIRE - Mon Nov 03, 7:03AM CST
Los Angeles, CA / ACCESSWIRE / November 3, 2014 / The National Cancer Institute (NCI) spends upwards of $4.9 billion each year on cancer research.
INO: 9.11 (-0.09), NWBO: 5.58 (+0.04), DNDN: 0.13 (-0.02), GALE: 1.49 (-0.02)

Time Magazine Warns Against Investing In Certain "Ebola Stocks"
ACCESSWIRE - Tue Oct 28, 8:22AM CDT
LOS ANGELES, CA / ACCESSWIRE / October 28, 2014 / Time Magazine is today warning investors that while developmental stage pharmas like Inovio Pharmaceuticals (NASDAQ:INO , NewLink Genetics Corp. (NASDAQ:NLNK), Tekmira Pharmaceuticals (NASDAQ:TKMR) and Sarepta Therapeutics (NASDAQ:SRPT) have all generated significant interest among stock market investors lately, there are good reasons to shy away from buying into experimental Ebola treatment therapies. But how can this be?
INO: 9.11 (-0.09), MRK: 57.46 (+0.25), PFE: 31.42 (-0.03), SRPT: 13.88 (+0.47), NLNK: 39.08 (+1.36), TKMR: 13.97 (+0.14), GSK: 42.85 (+0.11), NVS: 93.91 (+0.66)

TapImmune Provides Update on PolyStart(TM) Vaccine Platform Applicable to Cancer and Infectious Disease
Business Wire - Wed Oct 22, 7:30AM CDT
TapImmune, Inc. (OTCBB:TPIV), provides an update on the status of its PolyStart(TM) vaccine technology platform in light of recent global concerns regarding pandemic infections and emerging viral threats such as Ebola and Enterovirus. While the current focus of the Company's PolyStart technology is on TapImmune's cancer program (e.g., Her2/neu and folate receptor alpha antigens), the Company none-the-less strongly reaffirms that this core technology has widespread applicability in the development of vaccines for viral disease.

What's Next: Investors Place Ebola Pandemic Stock Bets
ACCESSWIRE - Mon Oct 06, 6:59AM CDT
Los Angeles, CA / October 6, 2014 / The recent outbreaks of Ebola in Africa and the first case found in the U.S. have also heightened the FDA's awareness of disease outbreaks and the need for stronger safety measures, but nothing gets investors salivating more that and constant media attention.
INO: 9.11 (-0.09), HEB: 0.22 (-0.02), TKMR: 13.97 (+0.14)

SeeThruEquity Issues Company Update on TapImmune Highlighting Positive Clinical Trial Data
ACCESSWIRE - Thu Sep 18, 8:03AM CDT
SeeThruEquity maintains price target of $6.97 per share and reiterates compelling valuation based on a number of factors including positive interim data on its Phase I clinical trial of folate receptor alpha antigens in ovarian and breast cancer

TapImmune Releases Positive Interim Data on Phase I Clinical Trial of Folate Receptor Alpha Antigens in Ovarian and Breast Cancer
Business Wire - Tue Sep 16, 7:30AM CDT
TapImmune Inc. (OTCQB:TPIV) is extremely pleased to report that analysis of the interim data from the first 13 patients in a Phase I clinical trial show that each of the patients treated have raised specific T-cell immune responses against a set of 5 naturally processed folate receptor alpha Class II antigenic epitopes. All five of the constituent peptides were found to be immunogenic and all patients developed immune responses to at least one and in most cases more than one of the vaccine peptides.

TapImmune, Inc. to Present at SeeThruEquity Microcap Conference
ACCESSWIRE - Thu Sep 04, 8:01AM CDT
Seattle, WA / ACCESSWIRE / September 4, 2014 / TapImmune, Inc. (OTCQB: TPIV), announces that company executives will attend and present at the SeeThruEquity Microcap Investor Conference to be held Thursday September 11th at the Convene Times Square, New York City. The presentation is scheduled for 10:00AM ET.

TapImmune Inc to Present at 16th Annual Rodman & Renshaw Healthcare Conference
ACCESSWIRE - Wed Sep 03, 9:42AM CDT
Seattle WA / ACCESSWIRE / September 3, 2014 / TapImmune, Inc. (OTCQB: TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease, will be featured as a presenting company at the 16th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The presentation will take place Wednesday, September 10th at 2:30 p.m. EDT in the Kennedy I Salon (4th floor) at the New York Palace Hotel in New York City.

SeeThruEquity Issues Update Note on TapImmune Highlighting New Grant Funded Clinical Trial and Recent Capital Raise of $2 Million
ACCESSWIRE - Tue Aug 19, 7:51AM CDT
New York, NY / ACCESSWIRE / August 19, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on TapImmune Inc. (OTCQB: TPIV).

TapImmune, Inc. Announces $2 Million Registered Direct Offering
Business Wire - Mon Aug 11, 11:21AM CDT
TapImmune, Inc. (the "Company" , (OTCQB:TPIV), today announced that it has entered into a definitive agreement with an institutional investor for a registered direct placement of $2,000,000 of common stock at a price of $1.06 per share.

TapImmune's New Clinical Trial in Advanced Stage Ovarian Cancer Expands the Use of Folate Receptor Alpha Peptide Antigens
Business Wire - Thu Aug 07, 8:23AM CDT
TapImmune Inc. (OTCQB:TPIV) is pleased to announce that a new grant funded Phase I clinical study on the safety and Immunogenicity of folate receptor alpha peptide vaccine in patients with advanced stage epithelial ovarian cancer has started at the Mayo Clinic, Rochester, MN. The folate receptor alpha peptides being used in this study are the same ones that are being used in a current Phase I study in breast and ovarian cancer. Folate receptor alpha is over a 100 fold elevated in 90% of ovarian cancer cells and is thus an excellent target for immunotherapy.

TapImmune Prevails in Legal Dispute with Michael Gardner
Business Wire - Thu Jul 24, 8:38AM CDT
TapImmune Inc. (OTCQB:TPIV), announces successful outcome of proceedings against Michael Gardner after almost 2 years of litigation.

New Immunotherapy Technologies Provide Hope In Breast and Ovarian Cancer
ACCESSWIRE - Wed Jul 23, 7:06AM CDT
Los Angeles / ACCESSWIRE / July 23, 2014 / Last month, TapImmune Inc. (OTCQB: TPIV) announced that Dr. Keith Knutson, PhD had been appointed to chair the company's scientific advisory board.

SeeThruEquity Issues Company Note on TapImmune Highlighting Valuation as Compared with Peers
ACCESSWIRE - Tue Jul 01, 8:02AM CDT
New York, NY / ACCESSWIRE / July 1, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a company note on TapImmune Inc. (OTCQB: TPIV).
JNJ: 104.59 (+0.31), KITE: 51.96 (+0.45), GALE: 1.49 (-0.02)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 52

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
CCTV-4 Revisits China's Enduring Academy Tradition

Updated Category News Views 76

Stone courtyards, old books and hard questions are getting prime time on CCTV-4, which is a more interesting programming bet than it may first appear. Enduring Chinese Academies, a ten-episode cultural exploration series from China Media Group's Global Chinese Programming Center, is built around a simple theme: “One academy, one spirit.” It begins airing November 22...

Continue Reading
Tigo's Guidance Gap Draws Lawsuit and Investor Scrutiny

Updated Category News Views 69

A Revenue Promise Hit the Wall Solar investing can turn ugly in a hurry when a supposedly near-term catalyst gets shoved down the calendar. That is the central bruise behind the securities class action involving Tigo Energy, not some arcane accounting footnote that only lawyers can love. The complaint alleges Tigo overstated the revenue contribution it expected from its...

Continue Reading
Sleep Number’s Couples Pitch Has Some Fine Print Too

Updated Category News Views 75

A thermostat war in the bedroom is a lousy reason to buy the wrong mattress. Yet that is the mundane, very real problem Sleep Number is leaning into after Expert Consumers named it a leading 2026 choice for couples seeking personalized sleep comfort. The company’s argument is straightforward: two people sharing a bed should not have to share one firmness setting, or...

Continue Reading
Trip.Best Expands Global Travel Discovery Footprint

Updated Category News Views 123

Sydney just became the map pin for a fairly serious travel-content land grab. Trip.Best, Trip.com Group's ranking brand, has rolled out its 2027 Annual Rankings with coverage of all seven continents for the first time. This is not an earnings release, and nobody should pretend a hotel list magically turns into revenue by lunchtime. Still, the jump from 85 to 98 annual...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 73

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
PayPal Adds a Risk Hand to Its Board at a Crucial Turn

Updated Category News Views 48

A Boardroom Hire With Some Actual Weight PayPal did not go hunting for another decorative résumé. Brian J. Lee, set to join the board on November 30, 2026, spent decades inside Goldman Sachs, including a stint as chief risk officer from 2019 through January 2025. For a payments company trying to sharpen its financial-services identity, that is a serious piece of...

Continue Reading
AlphaPoint's Approval Device Targets AI Attack Risk

Updated Category News Views 45

A Separate Screen May Be Worth More Than Another Patch AlphaPoint is taking a fairly old security instinct and aiming it at a very current headache: if the laptop is lying to the employee, do not let the laptop have the final say. Its newly introduced Approval Device is dedicated hardware with its own display, built to let authorized staff inspect and approve sensitive...

Continue Reading
Milwaukee County Contract Tests Wisconsin Labor Shift

Updated Category News Views 6

A unanimous first contract in a Milwaukee County department is not the sort of headline that rattles a trading screen, but it can tell you plenty about where the ground is moving. Public safety workers in the county Facilities Department have ratified their first agreement with Teamsters Local 344, according to the union. The vote matters less for any disclosed economic...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 79

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading

Top 5 Most Recently Viewed Articles

Identiv and InPlay Collaborate on Next-Gen IoT Innovations

Updated Category News Views 94

Identiv and InPlay Collaborate on Innovative IoT Solutions Identiv, Inc. (NASDAQ: INVE), a leader in RFID-enabled Internet of Things (IoT) solutions, has embarked on an exciting partnership with InPlay, known for its advanced wireless System-on-Chip (SoC) technologies. This dynamic collaboration aims to develop cutting-edge Bluetooth Low Energy (BLE)-enabled tags and IoT...

Continue Reading
Analyzing Stock Market Opportunities Amid Changing Trends

Updated Category News Views 164

Shifting Perspectives in Stock Valuation In the ever-evolving landscape of the stock market, today's best-performing stocks may soon reveal themselves as the riskiest investments. It's an intriguing shift, where what was once popular now stands at a crossroads, highlighting the fluctuations between bullish and bearish pathways. Currently, we face underlying pressures that...

Continue Reading
Investigation into Union Home Mortgage Data Breach Claims

Updated Category News Views 529

Understanding the Recent Union Home Mortgage Data Breach Union Home Mortgage Corp. (UHM), known as a significant player in the mortgage lending industry with a broad footprint, is facing scrutiny following a serious cybersecurity incident. The breach may have compromised sensitive personal information of numerous individuals. Impact of the Data Breach During the breach,...

Continue Reading
Projected Rise of Polyester Fiber Textile Market to $15.89B

Updated Category News Views 266

Growth Forecast of the Polyester Fiber Textile Market The Global Polyester Fiber Textile Market is poised for significant expansion, with projections indicating an increase from USD 12,850 million in 2024 to USD 15,890 million by 2030. This reflects a robust Compound Annual Growth Rate (CAGR) of 3.6% throughout the forecast period. Key Factors Driving Market Growth The...

Continue Reading
Paramount Elevates Dennis K. Cinelli to CFO and Adds Campion

Updated Category News Views 137

Paramount Welcomes New CFO and Board Member Paramount, a leading name in media and entertainment, has announced important changes to its executive team. Dennis K. Cinelli has been appointed as the new Chief Financial Officer, effective soon, while Andrew Campion has joined the Board of Directors. Transition in Financial Leadership Taking over from Andrew C. Warren, who...

Continue Reading